[Screening for prostate cancer--what does the evidence show?].
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is concluded that there is insufficient evidence to either support or refute the routine use of mass, selective or opportunistic screening compared to no screening in order to reduce prostate cancer mortality.
Abstract
A recent Cochrane review of the available randomised evidence for screening for prostate cancer is referred and discussed. The review concludes that there is insufficient evidence to either support or refute the routine use of mass, selective or opportunistic screening compared to no screening in order to reduce prostate cancer mortality. Until ongoing large, randomised screening trials mature and produce results that may prove otherwise, the Danish policy of not recommending PSA-based screening should be upheld.